Patients with cardiovascular disorders are particularly vulnerable to coronavirus disease (COVID-19).[@jeaa202-B1] We aimed to investigate the impact on COVID-19 patients' outcome of subclinical coronary artery disease (CAD), as evaluated by coronary calcium score (CCS) at chest high-resolution computed tomography (HRCT).

Consecutive patients with confirmed COVID-19 infection undergoing HRCT on admission at Padua University Hospital (Italy) were retrospectively evaluated. Subjects with known CAD were excluded. CCS was calculated at HRCT as described elsewhere.[@jeaa202-B2] A composite endpoint (CE) including in-hospital mortality and intensive care unit (ICU) admission was assessed in patients with high (≥400) and low--intermediate (\<400) CCS.^4^

Fifty-three hospitalized COVID-19 patients, mean age 65.3 ± 14.6 years, were considered for analysis. CCS ≥400 was found in 15.1% (*Table [1](#jeaa202-T1){ref-type="table"}*). The CE was observed in 75% of patients with high vs. 20% with low--intermediate CCS (*P* = 0.004). In-hospital mortality was 50% vs. 8.9% (*P* = 0.003). After adjustment for age and gender, CCS ≥400 was associated with occurrence of CE \[odds ratio (OR) 7.86, 95% confidence interval (CI) 1.16--53.01, *P* = 0.034\], as it was in a model including age and oxygen saturation on admission (OR 10.7, 95% CI 1.19--68.01, *P* = 0.035). Peak high-sensitivity (hs)-troponin was higher in non-survivors vs. survivors (1229.7 vs. 43.7 ng/L, *P* = 0.031).

###### 

Characteristics of patients with COVID-19 according to coronary calcium score

  Clinical characteristics           Total (53)         Calcium score \<400 (45)   Calcium score ≥400 (8)   *P*-value
  ---------------------------------- ------------------ -------------------------- ------------------------ -----------
  Age, years                         65.3 ± 14.6        62.9 ± 14.5                78.6 ± 4.9               **0.004**
  Female                             18 (34%)           16 (36%)                   2 (25%)                  0.561
  Hypertension                       28 (53%)           20 (46.5%)                 8 (100%)                 **0.005**
  Diabetes mellitus                  13 (24.5%)         11 (25%)                   2 (25%)                  1.00
  Smoking                            10 (19%)           3 (7%)                     7 (87.5%)                **0.001**
  ACEi/ARB use history               14 (26%)           10 (22%)                   4 (50%)                  0.120
  White blood cells, /μL             7.64 ± 5.12        7.31 ± 5.18                9.44 ± 4.55              0.282
  Neutrophils, /μL                   5.19 ± 3.29        5.02 ± 3.15                6.19 ± 4.17              0.393
  Lymphocytes, /μL                   1.76 ± 3.09        1.81 ± 3.32                1.49 ± 1.00              0.821
  Creatinine, mg/dL                  1.15 ± 1.20        1.15 ± 1.31                1.16 ± 0.34              0.993
  D-dimer, μg/L                      566.48 ± 1124.16   618.12 ± 1210.47           264.00 ± 78.24           0.447
  CRP, mg/L                          126.76 ± 96.91     115.53 ± 98.10             182.87 ± 71.55           0.072
  Procalcitonin, μg/L                1.41 ± 3.29        1.02 ± 2.10                3.15 ± 6.36              0.099
  SpO~2,~ %                          90 ± 10.35         91 ± 8.75                  88 ± 11.65               0.704
  Lactic acid, mmol/L                1.79 ± 0.97        1.79 ± 1.03                1.82 ± 0.82              0.956
  Hs-Troponin I on admission, ng/L   175 ± 450          23 ± 48                    754 ± 642                0.057
  Hs-Troponin I peak, ng/L           660 ± 1396         419 ± 1092                 1424 ± 2139              0.084
  Imaging features                                                                                          
   Consolidation, %                  16 (30%)           13 (29%)                   3 (37.5%)                0.685
   Ground-glass opacity, %           24 (45%)           19 (42%)                   5 (62.5%)                0.444
   Bilateral infiltration, %         40 (75.5%)         33 (73%)                   7 (87.5%)                0.662
  Medical treatment                                                                                         
   Antibiotic therapy                53 (100%)          45 (100%)                  8 (100%)                 1.00
   Antiviral therapy                 5 (9%)             4 (9%)                     1 (12.5%)                0.911
   Hydroxychloroquine                37 (70%)           30 (67%)                   7 (87.5%)                0.579
   Corticosteroid                    35 (66%)           29 (64%)                   6 (75%)                  0.937
   Tocilizumab                       9 (17%)            6 (13%)                    3 (37.5%)                0.186
  Outcomes                                                                                                  
   Composite endpoint                15 (28%)           9 (20%)                    6 (75%)                  **0.004**
   Intensive care unit admission     13 (24.5%)         8 (18%)                    5 (62.5%)                **0.028**
   Invasive mechanical ventilation   10 (19%)           7 (15.5%)                  3 (37.5%)                0.218
   Death                             8 (15%)            4 (9%)                     4 (50%)                  **0.003**

Values are mean ± SD or *n* (%). The values in bold represent statistical significant differences between groups.

ACEi, angiotensin converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CRP, C-reactive protein Hs-Troponin, high-sensitivity troponin.

The main finding of our study, the first to examine the potential impact of subclinical CAD on COVID-19 patients, is that CCS ≥400 is a marker of higher risk of worse in-hospital outcome. In our cohort, half of patients with CCS ≥400 died during hospitalization as compared with 8.9% with CCS \<400. Moreover, myocardial infarction (MI) was more frequent in patients with high CCS. These findings add to previous results from Wuhan,[@jeaa202-B1] showing that subjects with cardiovascular disease and evidence of MI had \>60% mortality.

The mechanism of MI in COVID-19 patients is unclear, but our preliminary experience suggests that the presence of significant subclinical CAD correlates with higher hs-troponin and worse outcome. We acknowledge that this is an early report on a relatively small population and that we were not able to include all potential confounders, thus the independent predicting role of CCS could not be definitively determined. Accordingly, we cannot exclude that the presence of high CCS is a marker of increased baseline risk rather than having a pathophysiological role in contributing to a worse prognosis. However, our data suggest that inclusion of CCS as part of routine HRCT evaluation might provide useful prognostic information in COVID-19 patients at no additional cost. It also remains to be further assessed whether MI is secondary to worsening of myocardial ischaemia in the setting of hypoxaemia or to plaque erosion/rupture triggered by systemic inflammatory response.

In conclusion, our preliminary, hypothesis-generating results suggest that evaluation of subclinical CAD at HRCT in COVID-19 patients might help in identifying subjects at higher risk of worse in-hospital outcome.
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